

# Clayton S Lewis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4643252/publications.pdf>

Version: 2024-02-01

13  
papers

279  
citations

1163117

8  
h-index

1281871

11  
g-index

13  
all docs

13  
docs citations

13  
times ranked

427  
citing authors

#	ARTICLE	IF	CITATIONS
1	Abstract 908: Preclinical <i>in vivo</i> characterization of a first-in-class humanized antibody targeting alternatively spliced tissue factor. , 2021, , .		0
2	A First-In-Class, Humanized Antibody Targeting Alternatively Spliced Tissue Factor: Preclinical Evaluation in an Orthotopic Model of Pancreatic Ductal Adenocarcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 691685.	2.8	5
3	Functional Characteristics and Regulated Expression of Alternatively Spliced Tissue Factor: An Update. <i>Cancers</i> , 2021, 13, 4652.	3.7	3
4	Enhanced Efficacy of Combination of Gemcitabine and Phosphatidylserine-Targeted Nanovesicles against Pancreatic Cancer. <i>Molecular Therapy</i> , 2020, 28, 1876-1886.	8.2	15
5	KLF11 (Kruppel-Like Factor 11) Modulates Arterial Thrombosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 309-310.	2.4	0
6	mTOR kinase inhibition reduces tissue factor expression and growth of pancreatic neuroendocrine tumors. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 169-182.	3.8	10
7	Alternatively spliced tissue factor levels are elevated in the plasma of patients with chronic liver diseases. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 1470-1475.	1.6	4
8	Targeting Sphingosine Kinases for the Treatment of Cancer. <i>Advances in Cancer Research</i> , 2018, 140, 295-325.	5.0	32
9	Activation of carbonic anhydrase IX by alternatively spliced tissue factor under late-stage tumor conditions. <i>Laboratory Investigation</i> , 2016, 96, 1234-1245.	3.7	12
10	Suppression of c-Myc and RRM2 expression in pancreatic cancer cells by the sphingosine kinase-2 inhibitor ABC294640. <i>Oncotarget</i> , 2016, 7, 60181-60192.	1.8	37
11	Antibody-based targeting of alternatively spliced tissue factor: a new approach to impede the primary growth and spread of pancreatic ductal adenocarcinoma. <i>Oncotarget</i> , 2016, 7, 25264-25275.	1.8	18
12	LCL124, a Cationic Analog of Ceramide, Selectively Induces Pancreatic Cancer Cell Death by Accumulating in Mitochondria. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 344, 167-178.	2.5	47
13	Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts. <i>Cancer Biology and Therapy</i> , 2011, 11, 524-534.	3.4	96